XOPENEX HFA
LOE Approachinglevalbuterol tartrate
NDAINHALATIONAEROSOL, METERED
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
XOPENEX HFA (levalbuterol tartrate) is 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic amp). First approved in 2005.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XOPENEX HFA is a metered-dose inhaler containing levalbuterol tartrate, the active R-enantiomer of albuterol, used to treat acute bronchospasm and reversible obstructive airway disease. It works by stimulating beta-2 adrenergic receptors on airway smooth muscle, increasing cyclic AMP and triggering muscle relaxation through inhibition of myosin phosphorylation. Levalbuterol is a functional antagonist that protects against bronchoconstrictor challenges regardless of the underlying cause.
$0.141MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D volume, signaling a shrinking brand team and shift toward generic transition management.
Mechanism of Action
2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.